Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.74 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24840151 | 1.00 | ADORA3 (0.74) | ADORA3ADORA1PDPK1MEN1GAA | |
| SCHEMBL24840150 | 0.93 | ADORA3 (0.81) | ADORA3ADORA1PDPK1MEN1GAA | |
| SCHEMBL25516147 | 0.92 | ADORA3 (0.88) | ADORA3ADORA1PDPK1MEN1GAA | |
| SCHEMBL24840152 | 0.83 | ADORA3 (0.55) | ADORA3ADORA1PDPK1MEN1GAA | |
| SCHEMBL24840156 | 0.81 | ADORA3 (0.58) | ADORA3ADORA1PDPK1MEN1GAA | |
| SCHEMBL24840155 | 0.80 | ADORA3 (0.59) | ADORA3ADORA1PDPK1MEN1GAA | |
| SCHEMBL25516139 | 0.78 | ALDH1A1 (0.48) | ADORA3ADORA1KMT2APOLB | |
| SCHEMBL25516138 | 0.78 | ALDH1A1 (0.48) | ADORA3ADORA1KMT2APOLB | |
| SCHEMBL24840280 | 0.77 | ALDH1A1 (0.46) | ADORA3ADORA1MEN1GAAKMT2A | |
| SCHEMBL26300002 | 0.75 | ALDH1A1 (0.40) | ADORA3ADORA1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230200219-A1 | A compound, an organic electroluminescent device and a display device | BEIJING ETERNAL MATERIAL TECHNOLOGY CO., LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230200219-A1 | A compound, an organic electroluminescent device and a display device | BEIJING ETERNAL MATERIAL TECHNOLOGY CO., LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| WO-2023093094-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY APPARATUS | 昆山国显光电有限公司 | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230200219-A1 | A compound, an organic electroluminescent device and a display device | L1CAM, VDAC2, CD274 | ADORA3 682/4885ADORA1 246/4885PDPK1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.